Source:http://linkedlifedata.com/resource/pubmed/id/19025919
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2008-12-1
|
| pubmed:abstractText |
The purpose of this study was to evaluate the influence of a steroid-free immunosuppression on hepatitis C virus (HCV) recurrence. A total of 198 liver transplantation (LT) patients were randomized to receive immunosuppression with basiliximab and cyclosporine, either with prednisone (steroid [St] group) or without prednisone (no steroids [NoSt] group). The group of 89 HCV-infected patients was followed up with protocol biopsies for 2 years after LT. This group of HCV patients are the patients evaluated in the present study. The rejection rate was 19% (St: 21% versus NoSt: 17%; P = 0.67). Patients in the St group had a slightly higher rate of bacterial infections (59% versus 38%; P = 0.05). Almost all patients had histological HCV-recurrence (St: 39/40 (97%) versus NoSt: 40/41 (97%); P = 1). The percentage of accumulated biopsies with grade 4 portal inflammation at 6 months, 1 year, and 2 years were, 23%, 49%, and 49% in the NoSt group, compared to 33%, 55%, and 69% in the St group, respectively (P = 0.04 at 2 years). The percentage of accumulated biopsies with grade 3 or 4 fibrosis at 6 months, 1 year, and 2 years were 0%, 8%, and 22% in the NoSt group, compared to 8%, 19%, and 31% in the St group, respectively. Immunosuppression without steroids in HCV patients is safe, reduces bacterial infections and metabolic complications, and improves histological short-term evolution of HCV recurrence.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Glucocorticoids,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Methylprednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/basiliximab
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1527-6473
|
| pubmed:author |
pubmed-author:BaliellasCarmeC,
pubmed-author:CastelloteJoseJ,
pubmed-author:FabregatJoanJ,
pubmed-author:FiguerasJoanJ,
pubmed-author:Garcia-GilAgustinA,
pubmed-author:LladóLauraL,
pubmed-author:RafecasAntoniA,
pubmed-author:RamosEmilioE,
pubmed-author:SerranoTeresaT,
pubmed-author:THOSIN Study Group,
pubmed-author:TorrasJaumeJ,
pubmed-author:XiolXavierX
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1752-60
|
| pubmed:meshHeading |
pubmed-meshheading:19025919-Adult,
pubmed-meshheading:19025919-Antibodies, Monoclonal,
pubmed-meshheading:19025919-Cyclosporine,
pubmed-meshheading:19025919-Evolution, Molecular,
pubmed-meshheading:19025919-Female,
pubmed-meshheading:19025919-Glucocorticoids,
pubmed-meshheading:19025919-Graft Rejection,
pubmed-meshheading:19025919-Hepacivirus,
pubmed-meshheading:19025919-Hepatitis C, Chronic,
pubmed-meshheading:19025919-Humans,
pubmed-meshheading:19025919-Immunosuppression,
pubmed-meshheading:19025919-Immunosuppressive Agents,
pubmed-meshheading:19025919-Liver Cirrhosis,
pubmed-meshheading:19025919-Liver Transplantation,
pubmed-meshheading:19025919-Male,
pubmed-meshheading:19025919-Methylprednisolone,
pubmed-meshheading:19025919-Middle Aged,
pubmed-meshheading:19025919-Prospective Studies,
pubmed-meshheading:19025919-Recombinant Fusion Proteins,
pubmed-meshheading:19025919-Recurrence
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study.
|
| pubmed:affiliation |
Department of Surgery, Liver Transplant Unit, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge, Barcelona, Spain. 31513llg@comb.es
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|